1
|
Wimo A. The End of the Beginning of the Alzheimer's Disease Nightmare: A Devil's Advocate's View. J Alzheimers Dis 2019; 64:S41-S46. [PMID: 29710714 DOI: 10.3233/jad-179905] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Although there have been so many failures in Alzheimer's disease (AD) modifying trials, there are still many compounds in the pipeline and the hope still remains that the entrance of disease-modifying treatment (DMT) for AD will positively and dramatically change the whole situation of AD treatment. However, if DMT does enter the market, it will be the beginning of a great number of challenges and problems. The current infrastructure for diagnostics of early (pre-dementia) AD does not have the capacity to meet the demands and expectations of the population. Neither is there capacity for treatment monitoring and follow-ups. If screening is considered, there will be a great risk for false positive cases and a great number of people who will have to undergo diagnostics. There will be high costs for diagnostics and treatment initially, while potential benefits will occur much later in other sectors than where the payers for treatment are. Although there are great hopes that prevention of cardiovascular risk factors and changes in lifestyle might impact the risk for dementia, there is still no consensus that this is the case. Finally, the relevance of different AD paradigms such as amyloid and tau is still a matter of discussion, particularly regarding the oldest old.
Collapse
Affiliation(s)
- Anders Wimo
- Department of Neurobiology, Division of Neurogeriatrics, Care Sciences and Society, Karolinska Institute, Huddinge, Sweden
| |
Collapse
|
2
|
Azria D, Blanquer S, Verdier JM, Belamie E. Nanoparticles as contrast agents for brain nuclear magnetic resonance imaging in Alzheimer's disease diagnosis. J Mater Chem B 2017; 5:7216-7237. [PMID: 32264173 DOI: 10.1039/c7tb01599b] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
Nuclear Magnetic Resonance Imaging (MRI) of amyloid plaques is a powerful non-invasive approach for the early and accurate diagnosis of Alzheimer's disease (AD) along with clinical observations of behavioral changes and cognitive impairment. The present article aims at giving a critical and comprehensive review of recent advances in the development of nanoparticle-based contrast agents for brain MRI. Nanoparticles considered for the MRI of AD must comply with a highly stringent set of requirements including low toxicity and the ability to cross the blood-brain-barrier. In addition, to reach an optimal signal-to-noise ratio, they must exhibit a specific ability to target amyloid plaques, which can be achieved by grafting antibodies, peptides or small molecules. Finally, we propose to consider new directions for the future of MRI in the context of Alzheimer's disease, in particular by enhancing the performances of contrast agents and by including therapeutic functionalities following a theranostic strategy.
Collapse
Affiliation(s)
- David Azria
- Institut Charles Gerhardt Montpellier, UMR 5253 CNRS-UM-ENSCM, Equipe Matériaux Avancés pour la Catalyse et la Santé, 8 rue de l'Ecole Normale, 34296 Montpellier Cedex 5, France.
| | | | | | | |
Collapse
|
3
|
Apostolova LG, Haider JM, Goukasian N, Rabinovici GD, Chételat G, Ringman JM, Kremen S, Grill JD, Restrepo L, Mendez MF, Silverman DH. Critical review of the Appropriate Use Criteria for amyloid imaging: Effect on diagnosis and patient care. ALZHEIMER'S & DEMENTIA (AMSTERDAM, NETHERLANDS) 2016; 5:15-22. [PMID: 28054024 PMCID: PMC5198877 DOI: 10.1016/j.dadm.2016.12.001] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
INTRODUCTION The utility of the Appropriate Use Criteria (AUC) for amyloid imaging is not established. METHODS Fifty-three cognitively impaired patients with clinical F18-florbetapir imaging were classified as early and late onset, as well as AUC-consistent or AUC-inconsistent. Chi-square statistics and t test were used to compare demographic characteristics and clinical outcomes as appropriate. RESULTS Early-onset patients were more likely to be amyloid positive. Change in diagnosis was more frequent in late-onset cases. Change in therapy was more common in early-onset cases. AUC-consistent and AUC-inconsistent cases had comparable rates of amyloid positivity. We saw no difference in the rate of treatment changes in the AUC-consistent group as opposed to the AUC-inconsistent group. DISCUSSION The primary role of amyloid imaging in the early-onset group was to confirm the clinically suspected etiology, and in the late-onset group in detecting amyloid-negative cases. The rate of therapeutic changes was significantly greater in the early-onset cases.
Collapse
Affiliation(s)
- Liana G. Apostolova
- Department of Neurology, Indiana University School of Medicine, Indianapolis, IN, USA
- Department of Radiological Sciences, Indiana University School of Medicine, Indianapolis, IN, USA
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA
- Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA
| | - Janelle M. Haider
- Department of Neurology, Cedar-Sinai Medical Center, Los Angeles, CA, USA
| | - Naira Goukasian
- Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA
| | - Gil D. Rabinovici
- Memory & Aging Center, Department of Neurology, University of California San Francisco, San Francisco, CA, USA
| | - Gael Chételat
- Inserm, EPHE, Université de Caen Basse-Normandie, Unité de Recherche 1077, Caen, France
| | - John M. Ringman
- Department of Neurology, Keck School of Medicine at the University of California Los Angeles, Los Angeles, CA, USA
| | - Sarah Kremen
- Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA
| | - Joshua D. Grill
- Department of Psychiatry and Human Behavior, University of California Irvine, Irvine, CA, USA
| | - Lucas Restrepo
- Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA
| | - Mario F. Mendez
- Department of Neurology, University of California Los Angeles, Los Angeles, CA, USA
- Department of Psychiatry, University of California Los Angeles, Los Angeles, CA, USA
| | - Daniel H. Silverman
- Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
| |
Collapse
|
4
|
Abstract
Antidementive drugs have made Alzheimer's disease a symptomatically treatable condition but have essentially bypassed vascular dementia. The complexity of its pathology, the variable pathognomonic manifestations, the absence of validated biomarkers and the continuum with Alzheimer's disease that makes vascular dementia a comparatively small market are the major contributing factors. This report discusses how drug repurposing can be harnessed to identify new therapeutic opportunities, where such efforts are already yielding promising results, and which ones must be considered failures. Most investigations address obvious aspects cerebral small vessel disease, but some early-stage developments attempt changes in gene expression or modulation of complex biological pathways. A stronger focus on the nature and dynamics of white matter lesions should yield additional molecular targets.
Collapse
Affiliation(s)
- Hermann AM Mucke
- HM Pharma Consultancy, Enenkelstrasse 28/32, A-1160 Vienna, Austria
| |
Collapse
|
5
|
Marra C, Gainotti G, Fadda L, Perri R, Lacidogna G, Scaricamazza E, Piccininni C, Quaranta D. Usefulness of an Integrated Analysis of Different Memory Tasks to Predict the Progression from Mild Cognitive Impairment to Alzheimer’s Disease: The Episodic Memory Score (EMS). J Alzheimers Dis 2015; 50:61-70. [DOI: 10.3233/jad-150613] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Camillo Marra
- Center for Neuropsychological Research, Institute of Neurology of the Policlinico Gemelli/Catholic University of Rome, Italy
| | - Guido Gainotti
- Center for Neuropsychological Research, Institute of Neurology of the Policlinico Gemelli/Catholic University of Rome, Italy
- IRCCS Fondazione Santa Lucia, Department of Clinical and Behavioral Neurology, Rome, Italy
| | - Lucia Fadda
- IRCCS Fondazione Santa Lucia, Department of Clinical and Behavioral Neurology, Rome, Italy
| | - Roberta Perri
- IRCCS Fondazione Santa Lucia, Department of Clinical and Behavioral Neurology, Rome, Italy
| | - Giordano Lacidogna
- Center for Neuropsychological Research, Institute of Neurology of the Policlinico Gemelli/Catholic University of Rome, Italy
| | - Eugenia Scaricamazza
- Center for Neuropsychological Research, Institute of Neurology of the Policlinico Gemelli/Catholic University of Rome, Italy
| | - Chiara Piccininni
- Center for Neuropsychological Research, Institute of Neurology of the Policlinico Gemelli/Catholic University of Rome, Italy
| | - Davide Quaranta
- Center for Neuropsychological Research, Institute of Neurology of the Policlinico Gemelli/Catholic University of Rome, Italy
| |
Collapse
|